see Here RB 4. DEVELOPING OUR PRODUCT PIPELINE The diagnostics...

see Here RB

4. DEVELOPING OUR PRODUCT PIPELINE
The diagnostics group (which now comprises Anteo Technologies and DIAsource ImmunoAssays SA) delivered on a number of key objectives to facilitate quicker commercialisation of Mix&Go. The following areas of activity stood out:

•  Point of care – the core ability of Mix&Go is to deliver the greatest value propositions in nano situations, where surface areas are miniaturised and traditionally difficult to work with. The ability to provide all of device value propositions in POC is profound. The AMG200nm kit was the first commercial product delivered to the POC market and continues to be at the forefront of commercial interactions. It forms an important component in a new tropical disease assay currently going through regulatory approval.

cheers